- Home
- MRVI vs ABVX Comparison
MRVI vs ABVX Comparison
Compare MRVI & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRVI
- ABVX
- Stock Information
- Founded
- MRVI 2014
- ABVX 2013
- Country
- MRVI United States
- ABVX France
- Employees
- MRVI N/A
- ABVX N/A
- Industry
- MRVI Biotechnology: Pharmaceutical Preparations
- ABVX
- Sector
- MRVI Health Care
- ABVX
- Exchange
- MRVI Nasdaq
- ABVX Nasdaq
- Market Cap
- MRVI 347.5M
- ABVX 407.6M
- IPO Year
- MRVI 2020
- ABVX N/A
- Fundamental
- Price
- MRVI $2.16
- ABVX $5.89
- Analyst Decision
- MRVI Hold
- ABVX Buy
- Analyst Count
- MRVI 10
- ABVX 8
- Target Price
- MRVI $7.59
- ABVX $34.63
- AVG Volume (30 Days)
- MRVI 3.8M
- ABVX 328.4K
- Earning Date
- MRVI 05-07-2025
- ABVX 03-24-2025
- Dividend Yield
- MRVI N/A
- ABVX N/A
- EPS Growth
- MRVI N/A
- ABVX N/A
- EPS
- MRVI N/A
- ABVX N/A
- Revenue
- MRVI $259,185,000.00
- ABVX $11,172,999.00
- Revenue This Year
- MRVI N/A
- ABVX $371.31
- Revenue Next Year
- MRVI $14.59
- ABVX N/A
- P/E Ratio
- MRVI N/A
- ABVX N/A
- Revenue Growth
- MRVI N/A
- ABVX 135.94
- 52 Week Low
- MRVI $2.07
- ABVX $5.50
- 52 Week High
- MRVI $11.56
- ABVX $16.63
- Technical
- Relative Strength Index (RSI)
- MRVI 28.06
- ABVX 36.23
- Support Level
- MRVI $2.07
- ABVX $5.60
- Resistance Level
- MRVI $2.43
- ABVX $7.85
- Average True Range (ATR)
- MRVI 0.20
- ABVX 0.61
- MACD
- MRVI 0.05
- ABVX -0.09
- Stochastic Oscillator
- MRVI 14.06
- ABVX 12.89
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.